Glaukos Corporation Common Stock (GKOS)

About GKOS

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The com…

Sector

Health Care

Industry

Medical/Dental Instruments

Employees

1,094

Website

www.glaukos.com

Fundamentals

1-day range

$177.77$182.23

Market cap

$10.08B

P/E (trailing)

—

P/E (forward)

356.65

EPS (trailing)

$-3.26

Dividend yield

—

Beta

0.66

Avg. volume

894.0K

Forecasts

13 analyst ratings

Glaukos Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• GKOS

  Glaukos Corporation Common Stock

  $179.56

  ▼ 1.29%
  Market cap $10.08BP/E —
  $73.16$191.62
• GMED

  Globus Medical Inc. Class A Common Stock

  $83.06

  ▲ 0.63%
  Market cap $11.06BP/E 21.55
  $54.15$101.4
• APLD

  Applied Digital Corporation Common Stock

  $25.37

  ▼ 7.56%
  Market cap $8.60BP/E —
  $13.16$50.73
• PODD

  Insulet Corporation Common Stock

  $145.15

  ▲ 1.21%
  Market cap $11.75BP/E 27.05
  $126.4$354.88
• TFX

  Teleflex Incorporated Common Stock

  $139.84

  ▲ 1.55%
  Market cap $6.18BP/E —
  $100.18$145
• BAX

  Baxter International Inc. Common Stock

  $26.12

  ▲ 0.77%
  Market cap $14.53BP/E —
  $15.73$30
• IRTC

  iRhythm Holdings Inc. Common Stock

  $120.22

  ▲ 3.34%
  Market cap $4.10BP/E —
  $100.85$212

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
  benzinga · 8/25/2026
• Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
  Benzinga · 8/25/2026
• Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
  Benzinga · 8/20/2026
• BTIG Maintains Buy on Glaukos, Raises Price Target to $202
  Benzinga · 8/20/2026
• Glaukos (GKOS) Price Target Increased by 21.95% to 196.94
  Fintel · 8/4/2026

• Joseph E. Gilliam · August 11, 2026 · Option Exercise

  10.0K @ $48.46
• Joseph E. Gilliam · August 11, 2026 · Option Exercise

  20.0K @ $55.18
• Joseph E. Gilliam · August 11, 2026 · Sale

  32.0K @ $180.49
• Joseph E. Gilliam · August 11, 2026 · Sale

  28.0K @ $178.89
• Alex R. Thurman · August 7, 2026 · Option Exercise

  20.0K @ $33.81
• Alex R. Thurman · August 7, 2026 · Sale

  20.0K @ $180.13
• Leana Wen · July 31, 2026 · Sale

  525 @ $167.63
• Alex R. Thurman · July 16, 2026 · Option Exercise

  10.0K @ $38.68
• Alex R. Thurman · July 16, 2026 · Sale

  10.0K @ $160
• Alex R. Thurman · July 9, 2026 · Option Exercise

  10.0K @ $38.68
• Alex R. Thurman · July 9, 2026 · Sale

  10.0K @ $155
• Alex R. Thurman · July 6, 2026 · Option Exercise

  10.0K @ $38.68
• Alex R. Thurman · July 6, 2026 · Sale

  10.0K @ $150
• Tomas Navratil · July 1, 2026 · Sale

  716 @ $139.06
• Tomas Navratil · June 16, 2026 · Sale

  1.5K @ $130.68

Institutional Ownership

March 31, 2026

Total shares held

54.72M

Total value held

$5.78B

Institutional holders

331